How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Lung Cancer Genomic Testing Market
- By Test Type: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Sanger Sequencing
- By Sample Type: Tissue Biopsy, Liquid Biopsy (Circulating Tumor DNA), Blood Sample, Pleural Effusion, Fine Needle Aspiration
- By Biomarker Type: EGFR Mutation Testing, ALK Rearrangement Testing, ROS1 Fusion Testing, KRAS Mutation Testing, BRAF Mutation Testing, PD-L1 Expression Testing
- By End User: Hospitals, Diagnostic Laboratories, Cancer Research Institutes, Specialty Clinics, Reference Laboratories
- By Technology Platform: Illumina Sequencing Platforms, Thermo Fisher Scientific Platforms, Qiagen Platforms, Roche Diagnostics Platforms, Bio-Rad Laboratories Platforms
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Next-Generation Sequencing (NGS) leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 312 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.187 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.195 →
Full report · locked preview
Everything inside the Lung Cancer Genomic Testing Market report
A complete, evidence-based study - 12 chapters and 131 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Sample Type 5
Biomarker Type 6
End User 5
Technology Platform 5
Companies profiled
Foundation Medicine
Inc. (a subsidiary of Roche)
Guardant Health Inc.
Caris Life Sciences
Tempus Labs Inc.
Invitae Corporation
Freenome Holdings Inc.
Personalis Inc.
Natera Inc.
Qiagen N.V.
Myriad Genetics Inc.
Biocept Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Foundation Medicine
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Inc. (a subsidiary of Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Guardant Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Caris Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Tempus Labs Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Invitae Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Freenome Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Personalis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Natera Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Qiagen N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Myriad Genetics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Biocept Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →PathAI Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Sophia Genetics SA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →OncoDNA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Genomic Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc. (a subsidiary of Exact Sciences)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,620M by 2033 · 7.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Next-Generation Sequencing (NGS)46.2
- Polymerase Chain Reaction (PCR)11.2
- Fluorescence In Situ Hybridization (FISH)15.6
- Immunohistochemistry (IHC)8.0
- Sanger Sequencing19.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,423M → $2,718M · 8.4%
Europe$991.8M → $1,789M · 7.7%
Asia Pacific$905.5M → $1,537M · 6.8%
Latin America$560.6M → $986.7M · 7.3%
Middle East and Africa$431.2M → $702.9M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.332026
7.342027
7.352028
7.362029
7.382030
7.382031
7.412032
7.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Foundation Medicine23.4
- Inc. (a subsidiary of Roche)15.8
- Guardant Health Inc.11.3
- Caris Life Sciences8.8
- Tempus Labs Inc.4.9
- Invitae Corporation7.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type12.9%
Sample Type19.8%
Biomarker Type17.5%
End User24.5%
Technology Platform25.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.1
- Europe23.1
- Asia Pacific19.9
- Latin America12.8
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Foundation Medicine | 88 | 80 | 98 | 90 | 88 | 80 | 87 |
| Inc. (a subsidiary of Roche) | 71 | 68 | 76 | 93 | 72 | 91 | 79 |
| Guardant Health Inc. | 64 | 87 | 80 | 68 | 88 | 63 | 75 |
| Caris Life Sciences | 63 | 81 | 73 | 62 | 80 | 63 | 70 |
| Tempus Labs Inc. | 55 | 66 | 58 | 77 | 65 | 62 | 64 |
| Invitae Corporation | 48 | 67 | 64 | 62 | 54 | 48 | 57 |
| Freenome Holdings Inc. | 50 | 43 | 48 | 58 | 50 | 49 | 50 |
| Personalis Inc. | 53 | 45 | 37 | 35 | 58 | 45 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Foundation Medicine
- Inc. (a subsidiary of Roche)
- Guardant Health Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Foundation Medicine | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Inc. (a subsidiary of Roche) | ✓ | − | ✓ | ✓ | ✓ | ✓ |
| Guardant Health Inc. | − | ◐ | ◐ | − | ✓ | ◐ |
| Caris Life Sciences | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Tempus Labs Inc. | ◐ | ◐ | − | ◐ | ◐ | − |
| Invitae Corporation | − | ✓ | ◐ | − | − | − |
| Freenome Holdings Inc. | − | − | − | ◐ | − | ◐ |
| Personalis Inc. | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Foundation Medicine87
2Inc. (a subsidiary of Roche)79
3Guardant Health Inc.75
4Caris Life Sciences70
5Tempus Labs Inc.64
6Invitae Corporation57
7Freenome Holdings Inc.50
8Personalis Inc.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Foundation MedicineInc. (a subsidiary of Roche)
Challenger2
Strong scale, closing on the leaders.
Guardant Health Inc.Caris Life Sciences
Contender2
Focused players with pockets of strength.
Tempus Labs Inc.Invitae Corporation
Niche2
Specialists in a single segment or region.
Freenome Holdings Inc.Personalis Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Lung Cancer Genomic Testing Market — a $254M beachhead inside a $4.48B market.
Beachhead (SOM)$254Mobtainable near-term
Serviceable (SAM)$1.76Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Next-Generation Sequencing (NGS)
Best fit — highest urgency & budget in Test Type.
Economic buyer77 fit
Polymerase Chain Reaction (PCR)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Fluorescence In Situ Hybridization (FISH)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Biomarker Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lung Cancer Genomic Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation14%
Closed-won5%
$9.2KCAC
$37KLTV
4.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Lung Cancer Genomic Testing Market is a high-growth opportunity — $4.03B by 2033, compounding at 10.1%.
TAM · 2025$1.86Btoday
TAM · 2033$4.03Bforecast
CAGR10.1%2027–2033
Cumulative$25.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.03BTotal addressable market
SAM$1.57BServiceable available market
SOM$330MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.03BLarge & growingTAM by 2033 at 10.1% CAGR
$1.57BServiceable nowreachable with today’s model
$330MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.15BBear6.6% CAGR
$4.03BBase10.1% CAGR
$5.16BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Lung Cancer Genomic Testing Market — a $8.95B market by 2033. Plan: grow share from 6.5% to 12.3%.
Market size · 2033$8.95Btotal addressable
Market CAGR6.3%2027–2033
Target share12.3%from 6.5% today
Revenue ambition$1.10Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.5% | 12.3% | Ahead |
| Revenue | $615M | $1.10B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.3% | 40.6% | On track |
| Customer retention | 89.6% | 92.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $152M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Lung Cancer Genomic Testing Market conversation — a $12.8B market you can size, segment and defend in minutes.
Market size · 2033$12.8Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers1,132+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 3 mopayback period
$72K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Foundation MedicineInc. (a subsidiary of Roche)Guardant Health Inc.Caris Life SciencesTempus Labs Inc.Invitae CorporationFreenome Holdings Inc.Personalis Inc.+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lung Cancer Genomic Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Lung Cancer Genomic Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Lung Cancer Diagnostics Kit Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportLung Cancer Biomarkers Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportLung Biopsy Needle Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportLung Assessment Device Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportLumpectomy Surgery Device Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportLumpectomy Medical Device Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportLumpectomy Device Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportLump and Neck Detectors Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportLumiracoxib Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportLuminol Blood Detection Reagent Spray Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportLuminex Multiplex Assays Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportLuminescent Cell Viability Assay Reagent Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.